5th Mar 2008 14:00
AGI Therapeutics plc05 March 2008 AGI Therapeutics to present at Cowen and Company 28th Annual Health Care Conference in Boston -- 4.45 p.m., Monday 17 March, 2008 -- Dublin, Ireland, 5 March 2008 - AGI Therapeutics plc ("AGI" or the "Company")(AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinaldrug products, today announces that the Company's President of U.S. Operations,Dr. David Young, and Chief Financial Officer, David Kelly, will make apresentation at the Cowen and Company 28th Annual Health Care Conference inBoston. The conference will be held at the Boston Marriott, Copley Place. AGI will present on Monday 17 March at 4.45 p.m. EST (9.45 p.m. GMT). A copy ofthe presentation will be available after the event on the AGI website atwww.agitherapeutics.com under the "Investors: Publications" tab. Contact Information: AGI Therapeutics plc. Tel: +353 1 449 3254David Kelly, Chief Financial Officer Financial Dynamics - UK Tel: +44 (0) 20 7269 7182Deborah Scott/Lara Mott Financial Dynamics - Ireland Tel: +353 1 663 3607Aisling Garvey Notes to Editors: About AGI Therapeutics plc AGI is a speciality pharmaceutical company which is focused on the developmentand commercialisation of differentiated drug products for gastrointestinal (GI)diseases and disorders. AGI's common shares are listed on the AlternativeInvestment Market of the London Stock Exchange (AIM) and on the Irish EnterpriseExchange of the Irish Stock Market (IEX) as AGI. The Company has a portfolio of product candidates derived from its KnownMolecular Entity (KME) approach to drug re-profiling and development. TheCompany's lead product candidate, Rezular, is an orally administeredtriple-action intestinal regulator, a first-in-class mechanism for the treatmentof Diarrhoea predominant Irritable Bowel Syndrome, (IBS-D). Rezular iscurrently in Phase III clinical trials. KME is a re-profiling methodology used by the Company to identify existingtherapeutic drugs which typically have been marketed for a number of years, haveestablished safety profiles and can be developed for new clinical indications orwith improved profiles in their existing clinical indications. In this way, theCompany seeks to reduce the risk, time and cost of new product development ascompared to the development of new chemical entities. AGI is developing a range of product candidates to treat a variety of prevalentGI diseases and disorders, including irritable bowel syndrome (IBS), dyspepsia,gastroparesis, ulcerative colitis, gastro-esophageal reflux disease (GERD) anddiarrhoea-related conditions such as chemotherapy-induced diarrhoea (CID). TheCompany is targeting areas of the GI therapeutic drug products market for itsproduct candidates where there are currently unmet medical needs or where theeffectiveness of existing drug therapies can be further improved. The Company has five active clinical stage product candidates which are eitherisomers or new drug delivery formulations of existing approved drugs, and whichhave established safety and tolerability profiles in their currently approvedclinical indications. For further information please see www.agitherapeutics.com Statements contained within this press release may contain forward-lookingcomments which involve risks and uncertainties that may cause actual results tovary from those contained in the forward-looking statements. In some cases, youcan identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', or 'continue'. Predictions andforward-looking references in this press release are subject to the satisfactoryprogress of research which is, by nature, unpredictable. Forward projectionsreflect management's best estimates based on information available at the timeof issue. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Potentially Ai